Inoviq Ltd · ASX:IIQ
Inoviq — Bell Potter Healthcare Conference 2023
21 slides from Inoviq's conference presentation, Nov 16, 2023
Slide 1: Investor Presentation: Bell Potter Healthcare Conference 2023
Investor Presentation Bell Potter Healthcare Conference 2023 ASX: IIQ | 16 November 2023
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by INOVIQ Limited (“INOVIQ” or the “Company”) Actual results, performance or achievements could be significantly different from those based on information available to it as at the date of this presentation. This presentation expressed in, or implied by
Slide 3: Company snapshot
Company snapshot $ Financial information (ASX:IIQ) Precision Disruptive Deep Ordinary shares2 92,018,702 focus technology pipeline Listed options2 2,611,349 52-week H/L2 A$0.990-0.460 Precision diagnostic and Proprietary technology Multi-stage pipeline exosome solutions to platforms driving future i
Slide 4: Board and Management
Board and Management | Healthcare, corporate & commercial experience DR GEOFF CUMMING MAX JOHNSTON PHILIP POWELL Non-Executive Chairman Non-Executive Director Non-Executive Director Healthcare and biotechnology director with Healthcare industry director and Healthcare industry director and chartered
Slide 5: INOVIQ CY23 achievements
INOVIQ CY23 achievements Focused on advancing the development and commercialisation of our SubB2M and EXO-NET platforms ✓ Clinically validated SubB2M technology and commenced BC monitoring study to enable partnering for LDT commercialisation ✓ Developed, validated and commissioned high-throughput EX
Slide 6: 3 business pillars
3 business pillars | Research tools, diagnostics and therapeutics 6
Slide 7: Products and pipeline
Products and pipeline | multi-stage research tools and cancer diagnostics • Exosome research tools for exosome isolation, biomarker discovery and diagnostics development • Blood tests for earlier and more accurate detection of breast, ovarian and other cancers PRODUCT INDICATION USE RESEARCH ASSAY C
Slide 8: SubB2M technology platform
SubB2M technology platform Scientific rationale • Cancer cells have a distinct feature of adding different sugar molecules to the proteins they produce, which sets them apart from normal cells • Neu5Gc is a sugar molecule commonly found in cancer cells • SubB2M is an engineered protein that preferen
Slide 9: SubB2M/CA15-3 test: Breast Cancer monitoring
SubB2M/CA15-3 test | Breast Cancer monitoring Clinical-stage and progressing towards partner-ready by Dec 2023 to enable LDT commercialisation • #1 cancer in women Development stage Breast cancer • 2.3m new cases of breast cancer worldwide pa1 • 7.8m survivors (5-year)1 Feasibility Completed • Earli
Slide 10: SubB2M/CA15-3 Test: data and plans
SubB2M/CA15-3 Test: data and plans SubB2M/CA15-3 and comparator CA15-3 test Clinical validation study | completed performance summary Breast Cancer All Stages SubB2M Comparator • Retrospective, case-control, clinical validation study in 483-samples AUC 0.93 0.70 demonstrated SubB2M/CA15-3 test detec
Slide 11: Breast cancer monitoring study: Study design
Breast cancer monitoring study | Study 1 design Study 1: To determine whether SubB2M/CA15-3 is equally expressing in women with different subtypes of breast cancer comparison between Pre-treatment serum types of BC Hormone receptor breast cancer (n=50) SubB2M/CA15-3 test Her2 positive breast cancer
Slide 12: Breast cancer monitoring study: Study design
Breast cancer monitoring study | Study 2 design Study 2: To determine the accuracy of SubB2M/CA15-3 to identify breast cancer recurrence comparison between recurrence and non- recurrence SubB2M/CA15-3 test no recurrent disease (n=12) comparison between test recurrent disease (n=12) IVD CA15-3 test 1
Slide 13: SubB2M/CA125 Test: Ovarian Cancer monitoring
SubB2M/CA125 Test | Ovarian Cancer monitoring Progressing towards clinical validation • #8 cancer in women & deadliest gynaecological cancer Development stage Ovarian cancer • 314k new cases of ovarian cancer worldwide pa1 • 823k survivors (5-year)1 Feasibility Completed • Earlier and more accurate
Slide 14: SubB2M: Go-to-market strategy
SubB2M | Go-to-market strategy SubB2M/CA15-3 test is expected to be partner-ready in December 2023 for commercialisation as a Laboratory Developed Test Complete IVD Secure IVD partners Commercialise first Build analytical medical device and approvals as an LDT in the USA and clinical development and
Slide 15: Market potential: Screening and monitoring tests
Market potential | Screening and monitoring tests Eligible screening Eligible monitoring Statistics1 Global Market size4,5 population2 population3 11.5 4.0 Ovarian cancer incidence 188.3 52,638 60.4 6 Ovarian 119m 367k $1.9b 54.7 GLOBAL Dx cancer 167.3 MARKET Ovarian cancer prevalence 154,831 (Milli
Slide 16: Exosomes: Diagnostic and therapeutic potential
Exosomes | Diagnostic and therapeutic potential • Exosomes are released by cells and perform key roles in intercellular communication, immune regulation and pathogenesis • Diseases elicit changes in the release of exosomes and their molecular cargo (DNA, RNA and proteins) • Exosomes can be isolated
Slide 17: EXO-NET: Exosome isolation tools
EXO-NET® | Exosome isolation tools Immunoaffinity magnetic bead-based capture system for isolation and analysis of exosomes Rapid, Simple, Compatible downstream Cost-effective analysis Enriches relevant EVs Reproducible Scalable Compatible with path Full automation lab workflow and platforms cGMP 17
Slide 18: EXO-NET research tools and services
EXO-NET research tools and services | commercially available EXO-NET PAN- CUSTOMISED EXOSOME BIOMARKER DIAGNOSTICS EXOSOME CAPTURE EXO-NET TOOLS ISOLATION DISCOVERY DEVELOPMENT EXO-NET is a research Design custom EV isolation using Biomarker discovery EV-based clinical tool for fast, efficient & EXO
Slide 19: Milestones and catalysts
Milestones and catalysts SubB2M and EXO-NET programs moving towards key inflection points H2 CY 2023 H1 CY 2024 ✓ EXO-NET co-marketing agreement with Promega Commercial progress SubB2M/CA15-3 LDT ✓ Results of EXO-OC equivalence study in plasma and serum (n=250) Results SubB2M/CA125 OC clinical valid
Slide 20: Summary
Summary | Next generation diagnostic solutions advancing towards key milestones 1 Innovative 2 Patented 3 Strong 4 Compelling Company Technology Pipeline Results Focused on next-gen diagnostic Proprietary SubB2M & NETs Deep pipeline Data for SubB2M and exosome- and exosome solutions to technologies
Slide 21: Contacts
Contacts INOVIQ Ltd 23 Normanby Road Notting Hill VIC 3168 Australia P +61 3 9548 7586 E info@inoviq.com W www.inoviq.com Dr Leearne Hinch | CEO E lhinch@inoviq.com M +61 400414416 21